Recap Hey guys! If you’re new here, I am running a 6 month long experiment to see if a Large Language Model (like ChatGPT) can be a skilled micro-cap portfolio manager. I give it real time data at the end of every trading day and it has full control over its assets. Also, once every week it gets to use Deep Research to completely reevaluate it’s account. Why microcaps? Because I want to see if ChatGPT can make intelligent decisions on picks that have little to no media attention (and also my budget is $100). Overview I promise the growth you’re about to see has been double checked, and I can’t believe it either. You may be thinking “Sure, I bet it beat the market by what, 5 percent?“ Nope, just take a look. Performance Graph Yes, that is 13.3% PURE ALPHA. One stock in particular has without a doubt been the reason for the massive growth. Since the the start of Week 1, CADL (Candel Therapeutics Inc) has surged 34% while being a major piece of the portfolio. ABEO (Abeona Therapeutics Inc) has also had impressive increase with 11% growth over the last five trading days. Who needs diversification, am I right? Portfolio Review Portfolio Review This was the current portfolio: Weekly Portfolio Summary (July 12–18, 2025) Weekly Portfolio Summary (July 12–18, 2025) ABEO: Started at $5.92, ended at $6.59 — up +11.32%CADL: Started at $6.43, ended at $6.74 — up +4.82%AZTR: Held steady at $0.23 — 0.00%IINN: Started at $1.40, ended at $1.41 — up +0.71% ABEO: Started at $5.92, ended at $6.59 — up +11.32% ABEO +11.32% CADL: Started at $6.43, ended at $6.74 — up +4.82% CADL +4.82% AZTR: Held steady at $0.23 — 0.00% AZTR 0.00% IINN: Started at $1.40, ended at $1.41 — up +0.71% IINN +0.71% New Updates Here was this week’s revaluation in ChatGPT’s own words: Summary of Recommended Actions (July 18, 2025) Sell Candel Therapeutics (CADL) – SELL to lock in +33% profit. The stock has run up on good news that is now priced in, and no major catalysts are expected until 2026. We will liquidate the 5 shares of CADL at ~$6.74 each (≈$33.7 total).Buy Actuate Therapeutics (ACTU) – NEW BUY. Using the CADL proceeds (and available cash $2.32), purchase ~6 shares of ACTU around $6.00 each. This initiates a position in a promising biotech with positive Phase 2 cancer results and potential short-term upside.Hold Abeona Therapeutics (ABEO) – HOLD. Maintain our 6 shares. Abeona’s strong cash position and imminent product launch support continued holding. We expect further value realization as ZEVASKYN sales ramp up.Hold Azitra (AZTR) – HOLD (Speculative). Keep our 55 shares of AZTR. Despite current slight loss, the upcoming Phase 1b data in Netherton syndrome (due Q4 2025) is a high-impact catalyst worth waiting fo. (No additional buying due to risk level, but hold existing stake.)Hold Inspira Technologies (IINN) – HOLD/Accumulating. Retain our 20 shares. Inspira’s $22.5M order and Nasdaq compliance mark a turning point. We will hold for anticipated further contracts and consider adding on dips as confidence grows. “ Sell Candel Therapeutics (CADL) – SELL to lock in +33% profit. The stock has run up on good news that is now priced in, and no major catalysts are expected until 2026. We will liquidate the 5 shares of CADL at ~$6.74 each (≈$33.7 total). Sell Candel Therapeutics (CADL) – SELL to lock in +33% profit. Candel Therapeutics (CADL) Buy Actuate Therapeutics (ACTU) – NEW BUY. Using the CADL proceeds (and available cash $2.32), purchase ~6 shares of ACTU around $6.00 each. This initiates a position in a promising biotech with positive Phase 2 cancer results and potential short-term upside. Buy Actuate Therapeutics (ACTU) – NEW BUY. Actuate Therapeutics (ACTU) Hold Abeona Therapeutics (ABEO) – HOLD. Maintain our 6 shares. Abeona’s strong cash position and imminent product launch support continued holding. We expect further value realization as ZEVASKYN sales ramp up. Hold Abeona Therapeutics (ABEO) – HOLD. Abeona Therapeutics (ABEO) Hold Azitra (AZTR) – HOLD (Speculative). Keep our 55 shares of AZTR. Despite current slight loss, the upcoming Phase 1b data in Netherton syndrome (due Q4 2025) is a high-impact catalyst worth waiting fo. (No additional buying due to risk level, but hold existing stake.) Hold Azitra (AZTR) – HOLD (Speculative). Azitra (AZTR) Hold Inspira Technologies (IINN) – HOLD/Accumulating. Retain our 20 shares. Inspira’s $22.5M order and Nasdaq compliance mark a turning point. We will hold for anticipated further contracts and consider adding on dips as confidence grows. “ Hold Inspira Technologies (IINN) – HOLD/Accumulating. Inspira Technologies (IINN) My Thoughts Safe to say holding through the major drawdown last week (-7% in a day) was move Buffet himself would be proud of. I am really impressed with the decision to lock in profits from CADL, especially considering the volatility in BioTech. Not many advisors would decide to lock in gains with such a high performing piece. Although, I am a little disappointed still holding the hyper speculative Azitra (AZTR). With such a massive lead already on the market,  I don’t think investing in risky binary catalyst is necessary. I would rather either hold it in pure cash or find a more solid company. But of course, ChatGPT has done just fine so far. GitHub Page and Email: GitHub Page and Email: If you’re curious about the code I’m using to automate results and graph, the GitHub page is: ChatGPT-Micro-Cap-Experiment ChatGPT-Micro-Cap-Experiment NOTE: * Nothing in the post or blog is financial advice. * If you have any suggestions or advice, my Gmail is : nathanbsmith729@gmail.com nathanbsmith729@gmail.com Thanks for reading! Subscribe to get an update every week and support my work.

Keep

Can ChatGPT Outperform the Market? Week 4

Can ChatGPT Outperform the Market? Week 2

Read My Stories

Too Long; Didn't Read

Make resilience your competitive advantage

Can ChatGpt Outperform the Market? Week 3

About Author

Comments

TOPICS

THIS ARTICLE WAS FEATURED IN

Related Stories

Untitled Story

Can ChatGPT Outperform the Market? Week 5

A Closer Look at the Top 3 Embedded Databases: SQLite, RocksDB, and DuckDB

The Attribution Illusion: How to Win When You Can't Track Everything

The Noonification: How Often Do NFTs Pass The Howey Test? (1/13/2023)

Darwin's Hybrid Intelligence to Align AI & Human Goals for Startups & VCs

Can ChatGPT Outperform the Market? Week 5

A Closer Look at the Top 3 Embedded Databases: SQLite, RocksDB, and DuckDB

The Attribution Illusion: How to Win When You Can't Track Everything

The Noonification: How Often Do NFTs Pass The Howey Test? (1/13/2023)

Darwin's Hybrid Intelligence to Align AI & Human Goals for Startups & VCs

Light-Mode

Classic

Newspaper

Dark-Mode

Neon Noir

Minty

HN StartUps